BioCentury
ARTICLE | Clinical News

AOBiome begins Phase Ib/IIa of B244 for allergic rhinitis

October 6, 2017 3:44 PM UTC

AOBiome LLC (Cambridge, Mass.) began a Phase Ib/IIa trial of B244 to treat seasonal allergic rhinitis. The double-blind, vehicle-controlled trial will enroll up to 24 healthy volunteers and up to 42 patients with a history of seasonal allergic rhinitis due to ragweed pollen. The primary endpoint is safety. Secondary endpoints include the change in Total Nasal Symptom Score (TNSS) after prophylaxis treatment with B244, subjective nasal symptom scores and nasal symptom-free response rate. AOBiome expects to complete the trial next March...

BCIQ Company Profiles

AOBiome Therapeutics Inc.